Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabigatran and Verapamil Drug-Drug Interaction Study
NCT02171533Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2008
- Primary completion
- Aug 2008
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of dabigatran in venous thromboembolism (VTE) and Atrial fibrillation (AFib), sponsored by Boehringer Ingelheim. Primary endpoint: Area under the concentration-time curve of total dabigatran from 0 extrapolated to infinity at 107 hours. Started Jun 2008; status: completed.
02
Drugs
dabigatran
03
Conditions
venous thromboembolism (VTE)Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT02171533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02171533.